Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Depreciation and Depletion (2016 - 2017)

Avalo Therapeutics' Depreciation and Depletion history spans 4 years, with the latest figure at $4906.0 for Q4 2017.

  • For Q4 2017, Depreciation and Depletion fell 23.2% year-over-year to $4906.0; the TTM value through Dec 2017 reached $21956.0, down 18.25%, while the annual FY2025 figure was $300000.0, 50.0% up from the prior year.
  • Depreciation and Depletion reached $4906.0 in Q4 2017 per AVTX's latest filing, down from $5361.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $7881.0 in Q4 2014 to a low of $4906.0 in Q4 2017.
  • Average Depreciation and Depletion over 4 years is $6169.3, with a median of $6148.0 recorded in 2015.
  • Peak YoY movement for Depreciation and Depletion: rose 22.99% in 2016, then fell 23.98% in 2017.
  • A 4-year view of Depreciation and Depletion shows it stood at $7881.0 in 2014, then fell by 21.99% to $6148.0 in 2015, then rose by 3.9% to $6388.0 in 2016, then dropped by 23.2% to $4906.0 in 2017.
  • Per Business Quant, the three most recent readings for AVTX's Depreciation and Depletion are $4906.0 (Q4 2017), $5361.0 (Q3 2017), and $5859.0 (Q2 2017).